Glaukos, RevOpsis Therapeutics Enter Exclusive License Agreement for Retinal Biologics
MT newswire2026/10/08 11:3607:36 AM EDT, 10/08/2026 (MT Newswires) -- Glaukos (GKOS) signed an agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a tri-specific biologic for the treatment of retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion, the company said Thursday. Financial terms of the agreement were not disclosed. The agreement also grants Glaukos exclusive rights to the RevMod platform for the discovery and development of up to four additional retinal biologics, while RO-104 is designed to block VEGF-A, VEGF-C and Ang-2, it added.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
